Effect of PGE1, PGI2, and PGF2 alpha analogs on collagen gel compaction in vitro and interstitial pressure in vivo.
Acute inflammation in skin is accompanied by increased negativity of interstitial fluid pressure (PIF), which will increase capillary fluid filtration and thereby potentiate edema formation. A series of studies indicates that the connective tissue cells in rat dermis are involved in the control of PIF and mediate this response. The present study describes a novel effect of prostaglandin (PG) E1 isopropyl ester, carbaprostacyclin (PGI2 analog), and latanoprost (PGF2 alpha analog) on edema formation and PIF in parallel with their action on the fibroblast-populated collagen gel contraction assay. The prostaglandins were injected subdermally in pentobarbital-anesthetized rats. PIF was measured with a servo-controlled counterpressure system after circulatory arrest had been induced with saturated potassium chloride. Circulatory arrest was induced to limit edema formation that would raise interstitial fluid volume and thereby attenuate a possible increased negativity of PIF. PGE1 (0.91 mM) and carbaprostacyclin (1.28 mM) lowered PIF from a control value of -0.8 +/- 0.4 mmHg to -3.0 +/- 0.4 (P < 0.01) and -3.7 +/- 0.9 (P < 0.01) mmHg, respectively, within 45 min in a dose-dependent manner. Edema formation was measured in separate experiments. PGE1 and carbaprostacyclin significantly increased interstitial fluid volume (extravascular 51Cr-EDTA space) at concentrations as low as 0.1 and 1.1 microM, respectively. Latanoprost had no effect on PIF or edema formation. However, latanoprost reversed, in a dose-dependent manner, an increased negativity of PIF accompanying the anaphylactic reaction to dextran. In the gel contraction assay with human diploid fibroblasts (AG 1518), a corresponding specificity was observed where PGE1 and carbaprostacyclin effectively inhibited gel contraction although latanoprost had no effect. Thus the present data demonstrate a novel effect of prostaglandins and provide further evidence for active modulation of PIF via loose connective tissue cells.
Berg
A
A
Department of Physiology, University of Bergen, Norway. Ansgar@pki.uib.no
Ekwall
A K
AK
Rubin
K
K
Stjernschantz
J
J
Reed
R K
RK
D000527:Alprostadil / Q000494:pharmacology*; D000818:Animals; D000077214:Becaplermin; D003094:Collagen / Q000737:chemistry*; D004487:Edema / Q000209:etiology; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000494:pharmacology; D005110:Extracellular Space / Q000187:drug effects / Q000502:physiology*; D005260:Female; D005782:Gels; D007700:Kinetics; D000077338:Latanoprost; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D011312:Pressure; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology*; D011465:Prostaglandins, Synthetic / Q000494:pharmacology*; D020574:Proto-Oncogene Proteins c-sis; D051381:Rats; D017208:Rats, Wistar
D005782:Gels; D010982:Platelet-Derived Growth Factor; D011461:Prostaglandins F, Synthetic; D011465:Prostaglandins, Synthetic; D020574:Proto-Oncogene Proteins c-sis; D000077214:Becaplermin; C026678:carboprostacyclin; D000077338:Latanoprost; D003094:Collagen; D011464:Epoprostenol; D000527:Alprostadil